
Myelofibrosis Program in Pharmaceutical Benefits Scheme (PBS) 012-18051126

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of the Pharmaceutical Benefits Scheme
(PBS) subsidised ruxolitinib for patients with myelofibrosis (MF).

Myelofibrosis and listing dates

Myelofibrosis (MF) is a serious bone marrow disorder that disrupts the
body's normal production of blood cells.

Listing dates are as follows:

-   ruxolitinib - February 2016

See Written Authority Required Drugs for further information.

Enquiries

Transfer enquiries about prescription arrangements to the Complex Drugs
Programs team and choose the team relevant to the condition treated.

The Resources page contains links to restriction and item codes, contact
details, application forms, and the Pharmaceutical Benefits Scheme (PBS)
and Services Australia websites.

Related links

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
